FDA

#Clinical trials #Data #FDA #HIV

HIV prevention options expanded in the US 

The US Food and Drug Administration (FDA) has approved a long-acting HIV prevention medication for the first time.   The drug  Developed by ViiV Healthcare, the medicine is long-acting cabotegravir injected once every two months. The FDA has approved the medicine for use by adults and adolescents weighing… Read More

#News #Trending News

#Antivirals #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer Covid pill effective against severe disease 

Pfizer has announced results from an analysis of 2,246 adults enrolled in its Phase II/III EPIC-HR (Evaluation of Protease Inhibition for Covid-19 in High-Risk Patients) trial of its novel Covid-19 oral antiviral candidate Paxlovid (nirmatrelvir [PF-07321332] tablets and ritonavir tablets).   The results   These results show that  Paxlovid significantly reduced the… Read More

#Covid-19 #News #Trending News

#Covid-19 #FDA

FDA authorises Eli Lilly Covid therapy for under-12s

Paediatric patients from birth to 12 years old can now be treated with an antibody drug for Covid-19. The US Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab and etesevimab to be administered together in high-risk paediatric patients for the treatment of mild to… Read More

#Covid-19 #News

#Biotherapeutics #Clinical trial #Covid-19 #FDA

UK becomes first country to approve a Covid-19 antiviral pill 

The MHRA has authorised Merck and Ridgeback Biotherapeutics’ molnupiravir pill for the treatment of at-risk Covid-19 patients, following positive clinical trial results. Molnupiravir is the first oral antiviral medicine authorised for the treatment of mild-to-moderate Covid-19 in adults with a positive SARS-CoV-2 diagnostic test and who have at least one risk… Read More

#News

#Covid-19 #EMA #FDA #Immunology / Virology & Vaccines #Pfizer

Pfizer and BioNTech submit data for the vaccination of children 5 to 12 years 

Pfizer and BioNTech have submitted data supporting the vaccination of children 5 to 12 years of age with Comirnaty (Covid-19 mRNA vaccine) to the European Medicines Agency (EMA) for a variation of the Conditional Marketing Authorization (CMA) in the European Union (EU). According to The New York Times, federal regulators evaluated the… Read More

#News

#Clinical trials #FDA #Muscles

FDA Fast Track designation for limb-girdle muscular dystrophy 

BridgeBio has been granted Fast Track designation United States Food and Drug Administration (FDA) for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received in 2021.  BridgeBio’s LGMD2i investigational therapy… Read More

#News

#Covid-19 #FDA #In vitro

FDA-approved drugs reduced SARS-CoV-2 infection in lab 

An in vitro study of drugs already approved by the US Food and Drug Administration (FDA) to treat a range of conditions has shown eight of them are also effective in slowing SARS-CoV-2 replication in infected human cells. The team led by University of Manchester scientists used the drugs… Read More

#News

#Clinical trials #Drug development #FDA

FDA grant ODD for hyperammonemia in inborn errors of metabolism

Versantis’ lead product candidate VS-01 has been has granted orphan drug designation (ODD) by the Food and Drug Administration (FDA) for the treatment of hyperammonemia (HA) in inborn errors of metabolism (IEM).   “This orphan drug designation from the FDA validates the scientific rationale of VS-01 in a… Read More

#News

Covid-19
#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna submits initial data to FDA for Covid-19 vaccine booster 

Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world… Read More

#News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Pfizer

This week in drug discovery (23-27 August) 

News round-up by DDW’s Megan Thomas for 23-27 August  The Covid-19 pandemic has undoubtedly put virology back on the drug discovery map and this week, DDW’s Megan Thomas has rounded up five stories which show updates and advancements in the fight against the virus.  … Read More

#News #Trending News

#Covid-19 #FDA #Immunology / Virology & Vaccines #Moderna #Regulatory

Moderna submits BLA to FDA for Covid-19 vaccine 

Moderna has completed the rolling submission process for its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for the full licensure of the its Covid-19 vaccine for active immunisation to prevent Covid-19 in individuals 18 years of age and older. As part of the completed BLA submission, Moderna has requested Priority… Read More

#Covid-19 #News #Trending News

#Comirnaty #Covid-19 #FDA #Immunology / Virology & Vaccines #Pfizer #Regulatory

Full FDA approval for Pfizer-BioNTech Covid-19 vaccine 

The US Food and Drug Administration (FDA) has approved the Biologics License Application for the Pfizer-BioNTech Covid-19 vaccine. It will now be marketed as Comirnaty for the prevention of Covid-19 disease in individuals 16 years of age and older.  It is the first COVID-19 vaccine to be granted approval by the FDA.  The vaccine continues to… Read More

#Covid-19 #News #Trending News

#Alzheimer's #Drug development #Drug discovery #FDA #Research

Historic breakthrough in the treatment of Alzheimer’s

The US Food and Drug Administration (FDA) has approved Biogen’s regulatory application for the use of aducanumab in the treatment of Alzheimer’s disease, which removes amyloid from brains. Aducanumab is the first new Alzheimer’s drug in nearly 20 years, and there is reportedly mixed evidence over its efficacy. However, according… Read More

#News

#Biotherapeutics #Cell therapy #FDA #Tumour biology

What FDA Clearance means for GammaDelta cell cancer therapy

GammaDelta Therapeutics’ Investigational New Drug (IND) application has been cleared by the US Food and Drug Administration (FDA) for its allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy, GDX012, to be investigated as a treatment for haematological malignancies. The FDA also granted orphan drug designation to allogeneic Vδ1… Read More

#News

#API #FDA #GMP #Regulatory

New whitepaper: FDA guidelines for GMP of API

One of the key elements of quality control in pharmaceutical manufacturing is cGMP compliance. As your product moves closer to market, cGMP requirements change and become more stringent. Dalton Pharma Services has created a whitepaper to download, FDA Guidelines for GMP of API. Featured in this whitepaper which you… Read More

#News

#Biotechnology #Drug development #FDA #Research

The FDA expands lung-on-a-chip collaboration with CN Bio

The US. Food and Drug Administration (FDA) has extended its research collaboration with CN Bio for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using… Read More

#News